The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma

Andrés J.M. Ferreri, Giuseppina P. Dognini, Osnat Bairey, Arpad Szomor, Carlos Montalbán, Barbara Horvath, Judit Demeter, Lilj Uziel, Riccardo Soffietti, John F. Seymour, Achille Ambrosetti, Rein Willemze, Maurizio Martelli, Giuseppe Rossi, Anna Candoni, Amalia De Renzo, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalBritish Journal of Haematology
Volume143
Issue number2
DOIs
Publication statusPublished - Oct 1 2008

Keywords

  • Anti-CD20 therapy
  • Extranodal lymphoma
  • Immunotherapy
  • Intravascular large B-cell lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Ferreri, A. J. M., Dognini, G. P., Bairey, O., Szomor, A., Montalbán, C., Horvath, B., Demeter, J., Uziel, L., Soffietti, R., Seymour, J. F., Ambrosetti, A., Willemze, R., Martelli, M., Rossi, G., Candoni, A., De Renzo, A., Doglioni, C., Zucca, E., Cavalli, F., & Ponzoni, M. (2008). The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. British Journal of Haematology, 143(2), 253-257. https://doi.org/10.1111/j.1365-2141.2008.07338.x